Diagnostic value of sclerostin, RANKL, oxidized LDL, and phoenixin-14 levels in acute ischemic stroke.

IF 2.1 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarkers in medicine Pub Date : 2026-03-01 Epub Date: 2026-03-13 DOI:10.1080/17520363.2026.2641471

Derya Öztürk, Fatih Özcelik, Bedriye Müge Sönmez, Ertuğrul Altınbilek, Ayşe Beyza Bekgöz, Serpil Bulut, Selin Çelik, Adem Melekoğlu, Abuzer Coşkun, Mustafa Çalık

{"title":"Diagnostic value of sclerostin, RANKL, oxidized LDL, and phoenixin-14 levels in acute ischemic stroke.","authors":"Derya Öztürk, Fatih Özcelik, Bedriye Müge Sönmez, Ertuğrul Altınbilek, Ayşe Beyza Bekgöz, Serpil Bulut, Selin Çelik, Adem Melekoğlu, Abuzer Coşkun, Mustafa Çalık","doi":"10.1080/17520363.2026.2641471","DOIUrl":null,"url":null,"abstract":"Aims: Acute ischemic stroke (AIS) is a leading cause of mortality and morbidity, yet largely preventable. An urgent clinical need exists for new biomarkers that enable early, noninvasive, and accurate diagnosis, even before the incident occurs. This study aims to determine the valency of serum sclerostin (SOST), receptor activator of nuclear factor-kappa B ligand (RANKL), oxidized low-density lipoproteins (OxLDL), and phoenixin-14 in AIS.Patients and methods: A case-control study was conducted in the emergency department (ED) of a tertiary care hospital between June 2024 and September 2024, including 48 patients with AIS and 40 healthy individuals. The enzyme-linked immunosorbent assay was used to determine the levels of SOST, OxLDL, RANKL, and phoenixin-14. Diagnostic accuracy and independent associations with AIS were examined.Results: Biomarker levels were significantly higher in AIS group. SOST was the best, with an area under the curve of 0.809. A one-unit increase in SOST and OxLDL levels increased the probability of stroke by 1.418 and 1.006 times, respectively.Conclusions: SOST, OxLDL, RANKL, and phoenixin-14 May be complementary markers that warrant further validation, even though the results show an association rather than a causal relationship, suggesting they might be useful for differentiating AIS from healthy controls.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"233-240"},"PeriodicalIF":2.1000,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13007432/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2026.2641471","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/13 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: Acute ischemic stroke (AIS) is a leading cause of mortality and morbidity, yet largely preventable. An urgent clinical need exists for new biomarkers that enable early, noninvasive, and accurate diagnosis, even before the incident occurs. This study aims to determine the valency of serum sclerostin (SOST), receptor activator of nuclear factor-kappa B ligand (RANKL), oxidized low-density lipoproteins (OxLDL), and phoenixin-14 in AIS.

Patients and methods: A case-control study was conducted in the emergency department (ED) of a tertiary care hospital between June 2024 and September 2024, including 48 patients with AIS and 40 healthy individuals. The enzyme-linked immunosorbent assay was used to determine the levels of SOST, OxLDL, RANKL, and phoenixin-14. Diagnostic accuracy and independent associations with AIS were examined.

Results: Biomarker levels were significantly higher in AIS group. SOST was the best, with an area under the curve of 0.809. A one-unit increase in SOST and OxLDL levels increased the probability of stroke by 1.418 and 1.006 times, respectively.

Conclusions: SOST, OxLDL, RANKL, and phoenixin-14 May be complementary markers that warrant further validation, even though the results show an association rather than a causal relationship, suggesting they might be useful for differentiating AIS from healthy controls.

查看原文本刊更多论文

硬化蛋白、RANKL、氧化LDL和凤凰素-14水平在急性缺血性脑卒中中的诊断价值。

目的：急性缺血性脑卒中（AIS）是死亡率和发病率的主要原因，但在很大程度上是可以预防的。临床迫切需要新的生物标志物，以便在事件发生之前进行早期、无创和准确的诊断。本研究旨在测定AIS患者血清硬化蛋白（SOST）、核因子- κ B配体受体激活剂（RANKL）、氧化低密度脂蛋白（OxLDL）和凤凰素-14的效价。患者和方法：2024年6月至2024年9月，在一家三级医院急诊科（ED）进行了一项病例对照研究，包括48名AIS患者和40名健康个体。采用酶联免疫吸附法测定SOST、OxLDL、RANKL和phoenixin-14的水平。检查了诊断的准确性和与AIS的独立关联。结果：AIS组生物标志物水平明显升高。SOST最佳，曲线下面积为0.809。SOST和OxLDL水平每增加1个单位，卒中的概率分别增加1.418倍和1.006倍。结论：SOST、OxLDL、RANKL和phoenixin-14可能是值得进一步验证的互补标记，尽管结果显示出一种关联而不是因果关系，这表明它们可能有助于区分AIS与健康对照。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.